Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Cannabis and development of dual diagnoses: A literature review.

Hanna RC, Perez JM, Ghose S.

Am J Drug Alcohol Abuse. 2017 Jul;43(4):442-455. doi: 10.1080/00952990.2016.1213273. Epub 2016 Sep 9.

PMID:
27612527
2.

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.

González-Pinto A, González-Ortega I, Alberich S, Ruiz de Azúa S, Bernardo M, Bioque M, Cabrera B, Corripio I, Arango C, Lobo A, Sánchez-Torres AM, Cuesta MJ; PEPs Group.

PLoS One. 2016 Aug 11;11(8):e0160949. doi: 10.1371/journal.pone.0160949. eCollection 2016.

3.

Unraveling Executive Functioning in Dual Diagnosis.

Duijkers JC, Vissers CT, Egger JI.

Front Psychol. 2016 Jun 28;7:979. doi: 10.3389/fpsyg.2016.00979. eCollection 2016. Review.

4.

Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

Buchy L, Seidman LJ, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Stone W, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J.

Psychiatry Res. 2015 Dec 30;230(3):878-84. doi: 10.1016/j.psychres.2015.11.033. Epub 2015 Nov 25.

5.

The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Volk DW, Lewis DA.

Biol Psychiatry. 2016 Apr 1;79(7):595-603. doi: 10.1016/j.biopsych.2015.06.015. Epub 2015 Jun 19. Review.

6.

Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study.

González-Blanch C, Gleeson JF, Koval P, Cotton SM, McGorry PD, Alvarez-Jimenez M.

PLoS One. 2015 Apr 7;10(4):e0122404. doi: 10.1371/journal.pone.0122404. eCollection 2015.

7.

Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):38-46. doi: 10.1016/j.schres.2015.01.017. Epub 2015 Mar 4.

8.

Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization.

Herzig DA, Sullivan S, Lewis G, Corcoran R, Drake R, Evans J, Nutt D, Mohr C.

Schizophr Bull. 2015 Mar;41 Suppl 2:S455-64. doi: 10.1093/schbul/sbu179. Epub 2014 Dec 27.

9.

The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.

Løberg EM, Helle S, Nygård M, Berle JØ, Kroken RA, Johnsen E.

Front Psychiatry. 2014 Nov 18;5:159. doi: 10.3389/fpsyt.2014.00159. eCollection 2014.

10.

Risk-taking in schizophrenia and controls with and without cannabis dependence.

Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA.

Schizophr Res. 2015 Feb;161(2-3):471-7. doi: 10.1016/j.schres.2014.11.009. Epub 2014 Nov 22.

11.

BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA.

Bahorik AL, Cornelius JR, Bangalore SS, Newhill CE, Keshavan MS, Eack SM.

Schizophr Res Cogn. 2014 Sep 1;1(3):160-163. No abstract available.

12.

Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Radhakrishnan R, Wilkinson ST, D'Souza DC.

Front Psychiatry. 2014 May 22;5:54. doi: 10.3389/fpsyt.2014.00054. eCollection 2014. Review.

13.

Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.

Smucny J, Stevens KE, Tregellas JR.

Pharmacol Biochem Behav. 2014 Mar;118:22-9. doi: 10.1016/j.pbb.2014.01.001. Epub 2014 Jan 10.

14.

Pathways from cannabis to psychosis: a review of the evidence.

Burns JK.

Front Psychiatry. 2013 Oct 14;4:128. doi: 10.3389/fpsyt.2013.00128. Review.

15.

The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study.

Potvin S, Bourque J, Durand M, Lipp O, Lalonde P, Stip E, Grignon S, Mendrek A.

Schizophr Res Treatment. 2013;2013:543842. doi: 10.1155/2013/543842. Epub 2013 Jul 17.

16.

Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Bahorik AL, Newhill CE, Eack SM.

Schizophr Bull. 2014 Jul;40(4):856-67. doi: 10.1093/schbul/sbt099. Epub 2013 Jul 24.

17.

An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use.

Løberg EM, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA, Hugdahl K.

Front Psychiatry. 2012 Oct 30;3:94. doi: 10.3389/fpsyt.2012.00094. eCollection 2012. Erratum in: Front Psychiatry. 2013;4:51.

18.

Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis.

Krysta K, Krupka-Matuszczyk I, Janas-Kozik M, Stachowicz M, Szymszal J, Rybakowski JK.

Med Sci Monit. 2012 Sep;18(9):CR581-6.

19.

MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.

Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, Ho BC.

Psychol Med. 2013 Mar;43(3):619-31. doi: 10.1017/S0033291712001559. Epub 2012 Jul 31.

20.

Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.

Braga RJ, Burdick KE, Derosse P, Malhotra AK.

Psychiatry Res. 2012 Dec 30;200(2-3):242-5. doi: 10.1016/j.psychres.2012.05.025. Epub 2012 Jul 18.

Supplemental Content

Support Center